Literature DB >> 12218852

[Characterization of renal masses].

O Hélénon1, M André, J M Correas, A Khairoune, S Merran, C Balleyguier.   

Abstract

The characterization of renal masses relies mainly on CT which remains the gold standard in the diagnosis of renal tumors and cysts. Ultrasound enables to diagnose benign cysts which account for the majority of incidentally detected renal masses. MR imaging is useful in the diagnosis of renal masses that remain indeterminate at CT. Moreover, it is efficient as a substitute when CT is contraindicated. Renal masses include three categories with respect to the size and the gross architecture of the lesion: indeterminate very small masses (less than 10mm in diameter); cystic renal masses and solid renal masses that exhibit postcontrast tumor tissue enhancement. Characterization of cystic renal masses relies mainly on the Bosniak classification which consists of four categories: benign simple cysts (cat I); minimally complicated cysts (cat II); indeterminate cystic renal masses that include cystic renal tumors (multiloculated or not) and complex cysts; cystic renal cell carcinomas (cat IV). Solid renal masses include pseudotumors (normal variants, renal dysmorphisms and inflammatory renal masses) and renal neoplasms among which CT enable to distinct: typical large renal cell carcinomas, typical fat-containing angiomyolipomas and indeterminate renal tumors.

Entities:  

Mesh:

Year:  2002        PMID: 12218852

Source DB:  PubMed          Journal:  J Radiol        ISSN: 0221-0363


  2 in total

1.  [Not Available].

Authors:  Ahmed Saadi; Mohamed Chlif; Yassine Ayari; Mourad Mohamed Gargouri; Ahmed Sellami; Sami Ben Rhouma; Yassine Nouira
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

2.  Incidence and predictive factors of benign renal lesions in Korean patients with preoperative imaging diagnoses of renal cell carcinoma.

Authors:  Seo Yong Park; Seong Soo Jeon; Seo Yeon Lee; Byong Chang Jeong; Seong Il Seo; Hyun Moo Lee; Han Yong Choi
Journal:  J Korean Med Sci       Date:  2011-02-25       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.